Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand

Cellular and Molecular Life Sciences

Volumn 70, Issue 19, 2013, Pages 3617-3629

  Azahri, Nor Saadah M ^a,b   Kavurma, Mary M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

Apoptosis; Cell survival; Gene expression; Regulation; TRAIL; Transcription factor

Indexed keywords

BCR ABL PROTEIN; BETA INTERFERON; DOXORUBICIN; EARLY GROWTH RESPONSE FACTOR 2; EARLY GROWTH RESPONSE FACTOR 3; ENTINOSTAT; FLUOROURACIL; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; PLATELET DERIVED GROWTH FACTOR BB; STAT1 PROTEIN; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; AUTOIMMUNE DISEASE; BINDING SITE; CANCER CELL; CELL DEATH; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CYTOKINE RESPONSE; EXON; GENE; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INFECTION; NONHUMAN; PATHOGENESIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SENDAI VIRUS INFECTION; T CELL LEUKEMIA; T LYMPHOCYTE ACTIVATION; TRAIL GENE; TRANSCRIPTION REGULATION; VASCULAR DISEASE;

EID: 84884349409     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-013-1264-x     Document Type: Review

References (100)

1. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang C-P, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687-12690
3. Mariani SM, Krammer PH (1998) Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 28:973-982
4. Secchiero P, Gonelli A, Corallini F, Ceconi C, Ferrari R, Zauli G (2010) Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. Atherosclerosis 211:333-336
5. Mariani S, Krammer P (1998) Surface expression of TRAIL/Apo2 ligand in activated mouse T and B cells. Eur J Immunol 28:1492-1498
6. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM (1997) The receptor for the cytotoxic ligand TRAIL. Science 276:111-113
7. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-818
8. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821
9. Degli-Esposti M (1997) Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 186:1165-1170
10. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, Ashkenazi A (1997) A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7:1003-1006
11. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7:813-820
12. Emery JG (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363-14367
13. Kavurma MM, Bennett MR (2008) Expression, regulation and function of trail in atherosclerosis. Biochem Pharmacol 75:1441-1450
14. Holoch PA, Griffith TS (2009) TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 625:63-72
15. Falschlehner C, Emmerich CH, Gerlach B, Walczak H (2007) TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39:1462-1475
16. Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, Ashkenazi A (2005) Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 280:40599-40608
17. Newsom-Davis T, Prieske S, Walczak H (2009) Is TRAIL the holy grail of cancer therapy? Apoptosis 14:607-623
18. Gong B, Almasan A (2000) Genomic organization and transcriptional regulation of human Apo2/TRAIL gene. Biochem Biophys Res Commun 278:747-752
19. Krieg A, Krieg T, Wenzel M, Schmitt M, Ramp U, Fang B, Gabbert HE, Gerharz CD, Mahotka C (2003) TRAIL-beta and TRAIL-gamma: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential. Br J Cancer 88:918-927
20. Woods DC, Alvarez C, Johnson AL (2008) Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells. Gynecol Oncol 108:632-640
21. Wang P, Lu Y, Li C, Li N, Yu P, Ma D (2011) Novel transcript variants of TRAIL show different activities in activation of NF-kappaB and apoptosis. Life Sci 89:839-846
22. Wang QD, Ji YS, Wang XF, Evers BM (2000) Isolation and molecular characterization of the 5′-upstream region of the human TRAIL gene. Biochem Biophys Res Commun 276:466-471
23. Li JH, Kirkiles-Smith NC, McNiff JM, Pober JS (2003) TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 171:1526-1533
24. Sato K, Niessner A, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM (2006) TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med 203:239-250
25. Chan J, Prado-Lourenco L, Khachigian LM, Bennett MR, Di Bartolo BA, Kavurma MM (2010) TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappaB-dependent manner. Circ Res 106:1061-1071
26. Di Bartolo BA, Chan J, Bennett MR, Cartland S, Bao S, Tuch BE, Kavurma MM (2011) TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe (-)/(-) mice. Diabetologia 54:3157-3167
27. Hameed AG, Arnold ND, Chamberlain J, Pickworth JA, Paiva C, Dawson S, Cross S, Long L, Zhao L, Morrell NW, Crossman DC, Newman CM, Kiely DG, Francis SE, Lawrie A (2012) Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. J Exp Med 209:1919-1935
28. Kavurma MM, Schoppet M, Bobryshev YV, Khachigian LM, Bennett MR (2008) TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappa B and induction of insulin-like growth factor-1 receptor. J Biol Chem 283:7754-7762
29. Lawrie A, Waterman E, Southwood M, Evans D, Suntharalingam J, Francis S, Crossman D, Croucher P, Morrell N, Newman C (2008) Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol 172:256-264
30. Schoppet M, Sattler AM, Schaefer JR, Hofbauer LC (2006) Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis 184:446-447
31. Azahri NS, Di Bartolo BA, Khachigian LM, Kavurma MM (2012) Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: mechanisms of PDGF-BB-mediated VSMC proliferation and migration. J Cell Biochem 113:2597-2606
32. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, Zauli G (2003) TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107:2250-2256
33. Secchiero P, Zerbinati C, Rimondi E, Corallini F, Milani D, Grill V, Forti G, Capitani S, Zauli G (2004) TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61:1965-1974
34. Corallini F, Celeghini C, Rizzardi C, Pandolfi A, Di Silvestre S, Vaccarezza M, Zauli G (2007) Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro. J Cell Physiol 212:89-95
35. Secchiero P, Candido R, Corallini F, Zacchigna S, Toffoli B, Rimondi E, Fabris B, Giacca M, Zauli G (2006) Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 114:1522-1530
36. Volpato S, Ferrucci L, Secchiero P, Corallini F, Zuliani G, Fellin R, Guralnik JM, Bandinelli S, Zauli G (2011) Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis 215:452-458
37. Patwardhan S, Gashler A, Siegel MG, Chang LC, Joseph LJ, Shows TB, Le Beau MM, Sukhatme VP (1991) EGR3, a novel member of the Egr family of genes encoding immediate-early transcription factors. Oncogene 6:917-928
38. Khachigian LM, Lindner V, Williams AJ, Collins T (1996) Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science 271:1427-1431
39. Fu M, Zhu X, Zhang J, Liang J, Lin Y, Zhao L, Ehrengruber MU, Chen YE (2003) Egr-1 target genes in human endothelial cells identified by microarray analysis. Gene 315:33-41
40. Santiago FS, Lowe HC, Day FL, Chesterman CN, Khachigian LM (1999) Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2. Am J Pathol 154:937-944
41. Almasan A, Ashkenazi A (2003) Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14:337-348
42. Wiley SR (2001) A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15:837-846
43. Fulda S, Wick W, Weller M, Debatin KM (2002) Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8:808-815
44. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC (2001) TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98:795-804
45. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163
46. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162
47. Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C (2009) TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 4:34-41
48. Tomek S, Horak P, Pribill I, Haller G, Rossler M, Zielinski CC, Pils D, Krainer M (2004) Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecol Oncol 94:107-114
49. Zhang Y, Zhang B (2008) TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 6:1861-1871
50. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I (2003) TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22:3842-3852
51. Kops GJ, Burgering BM (2000) Forkhead transcription factors are targets of signalling by the proto-oncogene PKB (C-AKT). J Anat 197(Pt 4):571-574
52. Ghaffari S, Jagani Z, Kitidis C, Lodish HF, Khosravi-Far R (2003) Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci USA 100:6523-6528
53. Rivera-Walsh I, Waterfield M, Xiao G, Fong A, Sun SC (2001) NF-kappaB signaling pathway governs TRAIL gene expression and human T-cell leukemia virus-I Tax-induced T-cell death. J Biol Chem 276:40385-40388
54. Chlichlia K, Moldenhauer G, Daniel PT, Busslinger M, Gazzolo L, Schirrmacher V, Khazaie K (1995) Immediate effects of reversible HTLV-1 tax function: T-cell activation and apoptosis. Oncogene 10:269-277
55. Los M, Khazaie K, Schulze-Osthoff K, Baeuerle PA, Schirrmacher V, Chlichlia K (1998) Human T cell leukemia virus-I (HTLV-I) Tax-mediated apoptosis in activated T cells requires an enhanced intracellular prooxidant state. J Immunol 161:3050-3055
56. Choi EA, Lei H, Maron DJ, Wilson JM, Barsoum J, Fraker DL, El-Deiry WS, Spitz FR (2003) Stat1-dependent Induction of Tumor Necrosis Factor-related Apoptosis-inducing Ligand and the Cell-Surface Death Signaling Pathway by Interferon B in Human Cancer Cells. Cancer Res 63:5299-5307
57. Miura Y, Tsujioka T, Nishimura Y, Sakaguchi H, Maeda M, Hayashi H, Dong M, Hyodoh F, Yata K, Wada H, Sugihara T, Otsuki T (2006) TRAIL expression up-regulated by interferon-gamma via phosphorylation of STAT1 induces myeloma cell death. Anticancer Res 26:4115-4124
58. Papageorgiou A, Dinney CP, McConkey DJ (2007) Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther 6:872-879
59. Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H (2004) Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J 23:3051-3060
60. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW (2002) Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285:1-24
61. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD (1998) How cells respond to interferons. Annu Rev Biochem 67:227-264
62. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N (2001) IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19:623-655
63. Veals SA, Schindler C, Leonard D, Fu XY, Aebersold R, Darnell JE Jr, Levy DE (1992) Subunit of an alpha-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins. Mol Cell Biol 12:3315-3324
64. Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, Wu GS, El-Deiry WS (2008) TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther 7:2034-2038
65. Xu J, Zhou JY, Wu GS (2006) Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy. Cancer Res 66:10092-10099
66. Xu J, Zhou J-Y, Wei W-Z, Philipsen S, Wu GS (2008) Sp1-mediated TRAIL induction in chemosensitization. Cancer Res 68:6718-6726
67. Xie RL, Gupta S, Miele A, Shiffman D, Stein JL, Stein G, Svan Wijnen AJ (2003) The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter. J Biol Chem 278:26589-26596
68. Ehrlich S, Infante-Duarte C, Seeger B, Zipp F (2003) Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes. Cytokine 24:244-253
69. Fanger NA, Maliszewski CR, Schooley K, Griffith TS (1999) Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 190:1155-1164
70. Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD, Griffith TS, Green DR, Schoenberger SP (2005) CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434:88-93
71. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H (1999) Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 189:1451-1460
72. Zauli G, Secchiero P (2006) The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 17:245-257
73. Oh S, Perera LP, Terabe M, Ni L, Waldmann TA, Berzofsky JA (2008) IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc Natl Acad Sci USA 105:5201-5206
74. Secchiero P, Melloni E, Heikinheimo M, Mannisto S, Di Pietro R, Iacone A, Zauli G (2004) TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood 103:517-522
75. Zhang XR, Zhang LY, Devadas S, Li L, Keegan AD, Shi YF (2003) Reciprocal expression of TRAIL and CD95L in Th1 and Th2 cells: role of apoptosis in T helper subset differentiation. Cell Death Differ 10:203-210
76. Falschlehner C, Schaefer U, Walczak H (2009) Following TRAIL's path in the immune system. Immunology 127:145-154
77. Azab NA, Rady HM, Marzouk SA (2012) Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement. Clin Rheumatol 31:1359-1364
78. Castellino G, Corallini F, Trotta F, Secchiero P (2007) Elevated levels of TRAIL in systemic lupus erythematosus are associated to the presence of anti-SSA/SSB antibodies. Lupus 16:479-482
79. Zai-Xing Y, Yan L, Hao W, Ye Z, Chang L, Ren-Qian Z (2008) Preliminary clinical measurement of the expression of TNF-related apoptosis inducing ligand in patients with ankylosing spondylitis. J Clin Lab Anal 22:138-145
80. Baetu TM, Kwon H, Sharma S, Grandvaux N, Hiscott J (2001) Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. J Immunol 167:3164-3173
81. Siegmund D, Hausser A, Peters N, Scheurich P, Wajant H (2001) Tumor necrosis factor (TNF) and phorbol ester induce TNF-related apoptosis-inducing ligand (TRAIL) under critical involvement of NF-kappa B essential modulator (NEMO)/IKKgamma. J Biol Chem 276:43708-43712
82. Fionda C, Nappi F, Piccoli M, Frati L, Santoni A, Cippitelli M (2007) Inhibition of trail gene expression by cyclopentenonic prostaglandin 15-deoxy-delta12,14-prostaglandin J2 in T lymphocytes. Mol Pharmacol 72:1246-1257
83. Lin C, Wei W, Zhang J, Liu S, Liu Y, Zheng D (2007) Formyl peptide receptor-like 1 mediated endogenous TRAIL gene expression with tumoricidal activity. Mol Cancer Ther 6:2618-2625
84. Droin NM, Pinkoski MJ, Dejardin E, Green DR (2003) Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses. Mol Cell Biol 23:7638-7647
85. Kirshner JR, Karpova AY, Kops M, Howley PM (2005) Identification of TRAIL as an interferon regulatory factor 3 transcriptional target. J Virol 79:9320-9324
86. Huang Y, Walstrom A, Zhang L, Zhao Y, Cui M, Ye L, Zheng JC (2009) Type I interferons and interferon regulatory factors regulate TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected macrophages. PLoS ONE 4:e5397
87. Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, Takeda K, Yagita H, Okumura K, Tanaka N, Taniguchi T, Ogasawara K (2001) Antiviral response by natural killer cells through TRAIL gene induction by IFN-α/β. Eur J Immunol 31:3138-3146
88. Wurzer WJ, Ehrhardt C, Pleschka S, Berberich-Siebelt F, Wolff T, Walczak H, Planz O, Ludwig S (2004) NF-kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation. J Biol Chem 279:30931-30937
89. Wurzer WJ, Planz O, Ehrhardt C, Giner M, Silberzahn T, Pleschka S, Ludwig S (2003) Caspase 3 activation is essential for efficient influenza virus propagation. EMBO J 22:2717-2728
90. Yang TT, Xiong Q, Enslen H, Davis RJ, Chow CW (2002) Phosphorylation of NFATc4 by p38 mitogen-activated protein kinases. Mol Cell Biol 22:3892-3904
91. Delling U, Tureckova J, Lim HW, De Windt LJ, Rotwein P, Molkentin JD (2000) A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavy-chain expression. Mol Cell Biol 20:6600-6611
92. Ho IC, Kim JH, Rooney JW, Spiegelman BM, Glimcher LH (1998) A potential role for the nuclear factor of activated T cells family of transcriptional regulatory proteins in adipogenesis. Proc Natl Acad Sci USA 95:15537-15541
93. Santini MP, Talora C, Seki T, Bolgan L, Dotto GP (2001) Cross talk among calcineurin, Sp1/Sp3, and NFAT in control of p21(WAF1/CIP1) expression in keratinocyte differentiation. Proc Natl Acad Sci USA 98:9575-9580
94. Wang Q, Zhou Y, Weiss HL, Chow C-W, Evers BM (2011) NFATc1 regulation of TRAIL expression in human intestinal cells. PLoS ONE 6:e19882
95. Lin T, Huang X, Gu J, Zhang L, Roth JA, Xiong M, Curley SA, Yu Y, Hunt KK, Fang B (2002) Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 21:8020-8028
96. Carlo-Stella C, Lavazza C, Di Nicola M, Cleris L, Longoni P, Milanesi M, Magni M, Morelli D, Gloghini A, Carbone A, Gianni AM (2006) Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand. Hum Gene Ther 17:1225-1240
97. Wajant H, Moosmayer D, Wuest T, Bartke T, Gerlach E, Schonherr U, Peters N, Scheurich P, Pfizenmaier K (2001) Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 20:4101-4106
98. Lawrence D (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7:383-385
99. Fulda S (2009) Caspase-8 in cancer biology and therapy. Cancer Lett 281:128-133
100. Baader E, Toloczko A, Fuchs U, Schmid I, Beltinger C, Ehrhardt H, Debatin KM, Jeremias I (2005) Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res 65:7888-7895